Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds

Completed · Phase 2/Phase 3

Conditions studied: Wound of Skin, Wound Heal, Wound Open, Surgical Wound

In brief

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin cancer surgically removed resulting in open surgical wounds less or equal to 1.5 cm. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in open surgical wounds less or equal to 1.5 cm.

Key facts

Study ID

NCT03452072

Run by

Brigham and Women's Hospital

People needed

87

Starts

2018-08-20

Expected to finish

2021-06-30

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age greater than 18 years
• Open surgical wound ≤1.5cm
• No hypersensitivity with use of 0.25% timolol gel

You may not qualify if…

• Age less than 18 years of age
• Open surgical wound >1.5cm
• Pregnant women
• Use of systemic retinoids within 1 month
• Any hypersensitivity with use of 0.25% timolol gel

Where it is running

• Mohs and Dermatologic Surgery Center, Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.